Skip to Content

Rosuvastatin Dosage

Applies to the following strength(s): 10 mg20 mg40 mg5 mg

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for Hyperlipidemia

Initial dose: 10 mg to 20 mg orally once a day
Maintenance dose: 5 mg to 40 mg orally once a day

Uses: To be used as an adjunct to diet in the following situations: to slow the progression of atherosclerosis; to reduce elevated total cholesterol (Total-C), low density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), non-high density lipoprotein cholesterol (nonHDL-C), and triglycerides, and to increase HDL-C in primary hyperlipidemia or mixed dyslipidemia; for the treatment of hypertriglyceridemia; for the treatment of primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia)

Usual Adult Dose for Hyperlipoproteinemia Type III (Elevated beta-VLDL + IDL)

Initial dose: 10 mg to 20 mg orally once a day
Maintenance dose: 5 mg to 40 mg orally once a day

Uses: To be used as an adjunct to diet in the following situations: to slow the progression of atherosclerosis; to reduce elevated total cholesterol (Total-C), low density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), non-high density lipoprotein cholesterol (nonHDL-C), and triglycerides, and to increase HDL-C in primary hyperlipidemia or mixed dyslipidemia; for the treatment of hypertriglyceridemia; for the treatment of primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia)

Usual Adult Dose for Hypertriglyceridemia

Initial dose: 10 mg to 20 mg orally once a day
Maintenance dose: 5 mg to 40 mg orally once a day

Uses: To be used as an adjunct to diet in the following situations: to slow the progression of atherosclerosis; to reduce elevated total cholesterol (Total-C), low density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), non-high density lipoprotein cholesterol (nonHDL-C), and triglycerides, and to increase HDL-C in primary hyperlipidemia or mixed dyslipidemia; for the treatment of hypertriglyceridemia; for the treatment of primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia)

Usual Adult Dose for Atherosclerosis

Initial dose: 10 mg to 20 mg orally once a day
Maintenance dose: 5 mg to 40 mg orally once a day

Uses: To be used as an adjunct to diet in the following situations: to slow the progression of atherosclerosis; to reduce elevated total cholesterol (Total-C), low density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), non-high density lipoprotein cholesterol (nonHDL-C), and triglycerides, and to increase HDL-C in primary hyperlipidemia or mixed dyslipidemia; for the treatment of hypertriglyceridemia; for the treatment of primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia)

Usual Adult Dose for Homozygous Familial Hypercholesterolemia

Initial dose: 20 mg orally once a day
Maintenance dose: 5 mg to 40 mg orally once a day

Comments:
-Response to therapy should be estimated from preapheresis LDL-C levels.

Use: For the reduction of LDL-C, Total-C, and ApoB in patients with homozygous familial hypercholesterolemia

Usual Adult Dose for Prevention of Cardiovascular Disease

Initial dose: 10 mg to 20 mg orally once a day
Maintenance dose: 5 mg to 40 mg orally once a day

Use: For individuals without clinically evident coronary heart disease but with an increased risk of cardiovascular disease (CVD) based on age 50 years or older in men and 60 years or older in women, high-sensitivity C-reactive protein test of 2 mg/L or higher, and presence of at least 1 additional CVD risk factor (e.g., hypertension, low HDL-C, smoking, or family history of premature coronary heart disease) to reduce the risk of stroke and myocardial infarction, and reduce the risk of arterial revascularization procedures

Usual Pediatric Dose for Heterozygous Familial Hypercholesterolemia

8 to less than 10 years: 5 mg to 10 mg orally once a day; safety and efficacy of doses greater than 10 mg/day have not been studied

10 to 17 years: 5 mg to 20 mg orally once a day; safety and efficacy of doses greater than 20 mg/day have not been studied

Comments:
-Dose adjustments should be made at intervals of 4 weeks or more.
-Doses should be based on recommended goal of therapy for each individual patient.

Use: As an adjunct to diet to reduce Total-C, LDL-C, and ApoB levels in patients with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C greater than 190 mg/dL or greater than 160 mg/dL and there is positive family history of premature cardiovascular disease (CVD) or 2 or more other CVD risk factors

Renal Dose Adjustments

Severe renal dysfunction (not on hemodialysis [CrCl less than 30 mL/min]):
-Initial dose: 5 mg orally once a day
-Maximum dose: 10 mg orally once a day

Liver Dose Adjustments

Chronic alcohol liver disease: Caution recommended.
Active liver disease or persistent elevations of hepatic transaminase levels: Contraindicated

Dose Adjustments

Asian Patients:
-Consider an initial dose of 5 mg orally once a day due to increased plasma drug concentrations; the increased systemic exposure should be taken into consideration when treating Asian patients not adequately controlled at doses up to 20 mg/day

Concomitant therapy with cyclosporine:
-Maximum dose: 5 mg orally once a day

Concomitant therapy with gemfibrozil:
-Initial dose: 5 mg orally once a day
-Maximum dose: 10 mg orally once a day

Concomitant therapy with atazanavir and ritonavir, lopinavir and ritonavir or simeprevir:
-Initial dose: 5 mg orally once a day
-Maximum dose: 10 mg orally once a day

Precautions

Safety and efficacy have been not established in patients younger than 8 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-May be taken orally once a day at any time; swallow whole with or without food
-Do not take 2 doses within 12 hours of each other.
-If antacids are needed, take antacids at least 2 hours after taking this drug.
-This drug should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and nonpharmacologic interventions alone has been inadequate.

Storage requirements:
-Protect from moisture.

General:
-When initiating therapy and/or switching from another HMG-CoA reductase inhibitor, the appropriate starting dose should be used first and only titrated according to patient's response and individual goals of therapy.
-Following initiation or upon titration of this drug, lipid levels should be analyzed within 2 to 4 weeks and the dosage adjusted accordingly.
-The 40 mg dose should be reserved for patients who have not achieved their LDL-C goal utilizing the 20 mg dose.
-This drug has not been studied in Fredrickson Type I and V dyslipidemias.

Monitoring:
-Genitourinary: Routine urinalysis testing should be performed
-Hepatic: Measure liver enzymes prior to initiation and if signs/symptoms of liver injury occur

Patient advice:
-Report immediately any unexplained muscle pain, tenderness, or weakness, especially if accompanied by malaise or fever, or if muscle signs/symptoms persist after discontinuing therapy.
-Females of childbearing age should be informed of the consequences of exposure to this drug during pregnancy; ask these patients to report pregnancies as soon as possible.
-Report any signs/symptoms that may be indicative of liver injury (e.g., fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice).

Hide